Reagan-Udall Launches Real-Word Evidence Collaboration For Sickle Cell Disease

FDA's Regan-Udall Foundation and the ASH Research Collaborative (ASH RC) are launching a collaborative project to gather real-world evidence for sickle cell disease, aiming to establish a consensus on using electronic health record data to better understand clinical outcomes among sickle cell patients and broaden research in the field. The "Real-World Evidence Consortium” will be a collaboration among clinicians, researchers, patients, federal regulators, informaticians and other industry stakeholders, according to the statement announcing the effort Wednesday (April 17). In electronic...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
Author: 

Burgess: Site Neutral Policies Key To Stable Doc Pay, Lower Overall Costs

Implementing site-neutral Medicare payment policies could replace the budget neutrality requirements that have driven cuts to physician pay while supporting independent practices and lowering overall health care costs for the American people, Rep. Michael Burgess (R-TX) suggested to HHS Secretary Xavier Becerra during a Wednesday (April 17) hearing on the President’s 2025 budget. Burgess also grilled Becerra on the lack of site neutral proposals in the budget, saying it indicates the administration favors large hospital systems over smaller providers, which...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

HRSA Cements Revisions For Improved 340B Dispute Resolution

The Health Resources and Services Administration (HRSA) has finalized modifications to the Administrative Dispute Resolution (ADR) process associated with the federal 340B drug discount program that are aimed at ensuring the process is less “trial-like” and more accessible to all stakeholders involved. It will be run by a panel of various subject matter experts and offers opportunities for decisions to be appealed, according to a final rule on the matter posted Thursday (April 18). Hospitals are pleased with the changes,...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

HRSA Cements Revisions For Improved 340B Dispute Resolution

The Health Resources and Services Administration (HRSA) has finalized modifications to the Administrative Dispute Resolution (ADR) process associated with the federal 340B drug discount program that are aimed at ensuring the process is less “trial-like” and more accessible to all stakeholders involved. It will be run by a panel of various subject matter experts and offers opportunities for decisions to be appealed, according to a final rule on the matter posted Thursday (April 18). Hospitals are pleased with the changes,...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Cassidy Skeptical Of FDA’s Approach To CDS Software Regulation

The top Republican on the Senate health committee is criticizing FDA’s approach to regulating clinical decision support (CDS) software, asking the agency for more information about how it crafted its guidance on the technology and whether it has documentation of threats posed to patients. Sen. Bill Cassidy (R-LA), the ranking Republican on the Senate Health, Education, Labor and Pensions Committee, wrote in a letter to FDA Commissioner Robert Califf that FDA’s guidance classifying some CDS software as medical devices subjects...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Secondary Author(s): 

AI Liability Framework Guide Circulates At Fed Agencies

The Connected Health Initiative recently released a comprehensive guide of actors in the artificial intelligence and machine learning value chain that it hopes will be used by federal agencies and lawmakers to help draft liability policies specific to AI in health care. The framework is being circulated among agencies as a reference for policy drafting and to help the agencies get on the same page the relevant actors involved in the development down through the deployment of algorithms. CHI said...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 

Second Stelara Biosimilar Selarsdi Gets FDA Approval

FDA has approved a second biosimilar version of the widely used injection psoriasis drug Stelara, which will be known as Selarsdi. It’s slated to enter the market on or after Feb. 21, 2025, following a settlement with Johnson & Johnson, the manufacturer of Stelara. If Stelara’s biosimilars capture a large enough market share, they could impact the drug’s status as one of the 10 drugs initially selected for CMS’ inaugural drug price negotiation program. The biosimilar makers Alvotech and Teva...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Second Stelara Biosimilar Selarsdi Gets FDA Approval

FDA has approved a second biosimilar version of the widely used injection psoriasis drug Stelara, which will be known as Selarsdi. It’s slated to enter the market on or after Feb. 21, 2025, following a settlement with Johnson & Johnson, the manufacturer of Stelara. If Stelara’s biosimilars capture a large enough market share, they could impact the drug’s status as one of the 10 drugs initially selected for CMS’ inaugural drug price negotiation program. The biosimilar makers Alvotech and Teva...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

NAIC Creates Steering Group In Response To Change Cyberattack

State insurance regulators have established a multi-state steering group that will look at how February’s cyberattack on Change Healthcare unfolded, assess how insurance carriers and other impacted entities reacted, and facilitate discussions about the response and recovery efforts with UnitedHealth Group and Change Healthcare, as well as ensure the country is better prepared for the next, inevitable attack. The National Association of Insurance Commissioners (NAIC) tells House Energy & Commerce Committee leaders the steering group, which is in its early...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
Author: 

Cassidy Requests More Info From HHS On Avian Flu Response

Sen. Bill Cassidy (R-LA), the ranking member of the Senate health committee, is requesting regular briefings from the Biden administration on the outbreak of avian influenza (H5N1) among livestock and wild animals in the United States, saying federal agencies must increase their transparency around interagency response to the outbreak. Cassidy wants to be provided with continued briefings on H5N1 in both animals and humans in addition to information on interagency coordination and guidance being provided to state and local agencies...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Pages

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.